Kiora Pharmaceuticals Files 8-K

Ticker: KPHMW · Form: 8-K · Filed: Oct 29, 2024 · CIK: 1372514

Kiora Pharmaceuticals Inc 8-K Filing Summary
FieldDetail
CompanyKiora Pharmaceuticals Inc (KPHMW)
Form Type8-K
Filed DateOct 29, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-disclosure, financials

Related Tickers: KPRX

TL;DR

Kiora Pharma (KPRX) filed an 8-K today - check for Reg FD and financials.

AI Summary

Kiora Pharmaceuticals, Inc. filed an 8-K on October 29, 2024, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Eyegate Pharmaceuticals Inc., is incorporated in Delaware and headquartered in Encinitas, CA.

Why It Matters

This filing indicates Kiora Pharmaceuticals is making a regulatory disclosure and providing financial statements, which could contain important updates for investors.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, which typically contains standard disclosures and financial information without immediate significant news.

Key Players & Entities

  • Kiora Pharmaceuticals, Inc. (company) — Registrant
  • Eyegate Pharmaceuticals Inc. (company) — Former company name
  • October 29, 2024 (date) — Date of report
  • Delaware (jurisdiction) — State of incorporation
  • Encinitas, CA (location) — Business address

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report information under Regulation FD Disclosure and to provide Financial Statements and Exhibits.

What was Kiora Pharmaceuticals Inc. formerly known as?

Kiora Pharmaceuticals, Inc. was formerly known as Eyegate Pharmaceuticals Inc.

In which state was Kiora Pharmaceuticals, Inc. incorporated?

Kiora Pharmaceuticals, Inc. was incorporated in Delaware.

What is the business address of Kiora Pharmaceuticals, Inc.?

The business address of Kiora Pharmaceuticals, Inc. is 332 Encinitas Blvd., Suite 102, Encinitas, CA 92024.

What is the Commission File Number for Kiora Pharmaceuticals, Inc.?

The Commission File Number for Kiora Pharmaceuticals, Inc. is 001-36672.

Filing Stats: 651 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2024-10-29 07:00:23

Key Financial Figures

  • $0.01 — nge on which registered: Common Stock, $0.01 par value KPRX NASDAQ Indicate by che

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On October 29, 2024, Kiora Pharmaceuticals, Inc. (the "Company") issued a press release announcing the regulatory approval to initiate ABACUS-2, a Phase 2 clinical trial of KIO-301 for the treatment of retinitis pigmentosa . A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. In addition, the Company hereby furnishes the updated investor presentation attached as Exhibit 99.2 to this Current Report on Form 8-K, which the Company may use in presentations to investors from time to time. The information furnished pursuant to Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference. The information furnished in this report, including Exhibits 99.1 and 99.2, shall not be deemed to constitute an admission that such information or exhibit is required to be furnished pursuant to Regulation FD or that such information or exhibit contains material information that is not otherwise publicly available. In addition, the Company does not assume any obligation to update such information or exhibit in the future.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Title 99.1 Press Release of Kiora Pharmaceuticals, Inc., dated as of October 29, 2024 99.2 Company Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). *Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KIORA PHARMACEUTICALS, INC. By: /s/ Melissa Tosca Melissa Tosca Chief Financial Officer (Principal financial and accounting officer) Date: October 29, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.